Instruction for use: Arthrofon

Dosage form: lozengers

ATX

L03 Immunostimulants

Pharmacological groups:

Anti-inflammatory agent; Immunomodulating agent [Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs]

Anti-inflammatory agent; Immunomodulating agent [Other immunomodulators]

The nosological classification (ICD-10)

K51 Ulcerative colitis: Colitis acute ulcerative; Colitis ulcerative; Ulcerative-necrotic colitis; Colitis ulcerative-hemorrhagic nonspecific; Colitis ulcerative and trophic; Colitis ulcerative idiopathic; Colitis ulcerative nonspecific; Nonspecific ulcerative colitis; Proctocolitis ulcers; Hemorrhagic purulent rectoxitis; Rectoccolitis ulcerative-hemorrhagic

M06.9 Rheumatoid arthritis, unspecified: Rheumatoid arthritis; Pain syndrome in rheumatic diseases; Pain in rheumatoid arthritis; Inflammation in rheumatoid arthritis; Degenerative forms of rheumatoid arthritis; Children's rheumatoid arthritis; Exacerbation of rheumatoid arthritis; Acute articular rheumatism; Rheumatic arthritis; Rheumatic polyarthritis; Rheumatoid arthritis; Rheumatic polyarthritis; Rheumatoid arthritis; Rheumatoid arthritis; Rheumatoid arthritis of active course; Rheumatoid periarthritis; Rheumatoid polyarthritis; Acute rheumatoid arthritis; Acute rheumatism

M19.9 Arthrosis, unspecified: Change in brush with osteoarthritis; Osteoarthritis; Arthrosis of large joints; Pain syndrome in osteoarthritis; Pain syndrome in acute inflammatory diseases of the musculoskeletal system; Pain syndrome in chronic inflammatory diseases of the musculoskeletal system; Deforming arthrosis; Deforming osteoarthritis; Deforming osteoarthritis of joints; Osteoarthritis in the acute stage; Osteoarthritis of large joints; Acute pain syndrome with osteoarthritis; Post-traumatic osteoarthritis; Rheumatic osteoarthritis; Spondylarthrosis; Chronic osteoarthritis

M25.9 Joint disease, unspecified: Arthropathy; Diseases of the joints; Swelling of the joints; Articular Syndrome; Edema after interventions during sprains

M47 Spondylosis: Spondyloarthrosis; Spondylarthrosis; Diseases of the spinal column; Spondylosis

Composition

Tablets for resorption 1 table.

Active substances: Antibodies to human TNF-α affinely purified * 0.003 g

Auxiliary substances: lactose monohydrate (lactose) - 0.267 g; MCC - 0.03 g; Magnesium stearate - 0.003 g

* Monohydrate is applied to lactose in the form of a water-alcohol mixture with a content of no more than 10-15 ng / g of the active form of the active substance

Description of dosage form

Tablets are flat-cylindrical, with a risk and chamfer, from white to almost white. On the side with the risk is inscribed MATERIA MEDICA, on the other side - ARTHROFON.

Pharmachologic effect

Mode of action - anti-inflammatory.

Pharmacodynamics

It is experimentally and clinically proven that the preparation modulates the production and functional activity of endogenous TNF-α in rheumatoid arthritis, osteoarthritis, osteochondrosis, back pain; Nonspecific ulcerative colitis (NUC). Has anti-inflammatory and analgesic effect. By reducing the production of a number of pro-inflammatory cytokines, inflammatory mediators prevent the progression of inflammatory lesions of tissues and target organs in inflammatory-degenerative diseases of joints and NNC.

Pharmacokinetics

The sensitivity of modern physicochemical methods of analysis (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow to estimate the content of ultra-small doses of antibodies in biological fluids, organs and tissues, which makes it technically impossible to study the pharmacokinetics of the drug Arthrofoon.

Indication of the drug Arthrofon

Rheumatoid arthritis, osteoarthrosis (including spondylarthrosis) and other joint diseases (during the remission period, it is possible to use the drug as a part of monotherapy, during an exacerbation - as part of complex therapy (with NSAIDs);

Nonspecific ulcerative colitis of mild and moderate severity.

Contraindications

Increased individual sensitivity to the components of the drug;

Children and adolescents under 18 years (due to lack of clinical experience).

Application of pregnancy and breastfeeding

The safety of the use of Arthrofoon in pregnant women and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.

Side effects

Possible reactions of increased individual sensitivity to the components of the drug.

Interaction

Incidents of incompatibility with other drugs have not been registered to date. Possible combination of the drug with NSAIDs.

Dosing and Administration

Inside, not during a meal. At one time - 2 tables. (Keep in your mouth until completely dissolved). The drug should be taken 2 times a day, in the evening and in the morning (before and after sleep).

Rheumatoid arthritis, osteoarthritis (including spondylarthrosis) and other joint diseases. The recommended duration of taking the drug is up to 6 months. With severe pain in the first 2-4 weeks of therapy, the drug is recommended to be taken up to 4 times a day as part of complex therapy. When the condition improves, gradually go to the reception of 2 table. 2 times a day.

NNC. The recommended duration of taking the drug is up to 6 months. At the expressed exacerbation of the disease (abdominal pain, diarrhea) in the first 2-4 weeks of therapy, the drug is recommended to be taken up to 4 times a day. When the condition improves, you should gradually switch to taking 2 tablets. 2 times a day.

Overdose

In case of an accidental overdose, dyspeptic events due to the excipients included in the formulation are possible.

Special instructions

On the 3-5th day after the beginning of treatment, there may be a moderately pronounced transient increase in pain syndrome or local manifestations of inflammation that does not require changes in the pharmacotherapy regimen. In some cases, with a marked increase in pain syndrome or local signs of inflammation, it is necessary to temporarily reduce the dose to 1-2 tablets / day. The composition of the drug includes lactose, and therefore it is not recommended to appoint patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase insufficiency.

Impact on the ability to drive vehicles and other potentially dangerous mechanisms. Does not affect.

Release Form

Lozenges. For 20 tablets. In a planar cell packaging made of PVC film and aluminum foil. For 1, 2 or 5 contour squares are placed in a pack of cardboard.

Manufacturer

LLC "NPF" MATERIA MEDICA HOLDING ". Russia, Moscow

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Arthrofon

At temperatures not higher than 25 ° C, in the original packaging.

Keep out of the reach of children.

Shelf life of the drug Arthrofon

3 years.

Do not use after the expiry date printed on the package.